AbbVie Inc. (ABBV)
USD 173.02
(-1.35%)
USD 173.02
(-1.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 45.53 Billion USD | 12.05% |
| 2022 | 40.64 Billion USD | 4.87% |
| 2021 | 38.75 Billion USD | 27.4% |
| 2020 | 30.41 Billion USD | 17.77% |
| 2019 | 25.82 Billion USD | 3.16% |
| 2018 | 25.03 Billion USD | 18.22% |
| 2017 | 21.17 Billion USD | 6.92% |
| 2016 | 19.8 Billion USD | 7.88% |
| 2015 | 18.35 Billion USD | 18.19% |
| 2014 | 15.53 Billion USD | 9.33% |
| 2013 | 14.2 Billion USD | 2.43% |
| 2012 | 13.87 Billion USD | 8.34% |
| 2011 | 12.8 Billion USD | 12.87% |
| 2010 | 11.34 Billion USD | 11.69% |
| 2009 | 10.15 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 8.22 Billion USD | -30.94% |
| 2024 Q3 | 10.29 Billion USD | -16.59% |
| 2024 Q2 | 12.28 Billion USD | 49.32% |
| 2023 Q2 | 9.62 Billion USD | 16.82% |
| 2023 Q4 | 11.91 Billion USD | 60.1% |
| 2023 FY | 45.53 Billion USD | 12.05% |
| 2023 Q1 | 8.23 Billion USD | -24.76% |
| 2023 Q3 | 7.44 Billion USD | -22.68% |
| 2022 Q1 | 9.48 Billion USD | -10.22% |
| 2022 Q3 | 9.79 Billion USD | -5.98% |
| 2022 Q4 | 10.95 Billion USD | 11.86% |
| 2022 FY | 40.64 Billion USD | 4.87% |
| 2022 Q2 | 10.41 Billion USD | 9.77% |
| 2021 Q2 | 9.43 Billion USD | 7.26% |
| 2021 Q3 | 9.95 Billion USD | 5.47% |
| 2021 Q4 | 10.56 Billion USD | 6.17% |
| 2021 FY | 38.75 Billion USD | 27.4% |
| 2021 Q1 | 8.79 Billion USD | -4.11% |
| 2020 Q3 | 7.85 Billion USD | 16.95% |
| 2020 Q4 | 9.17 Billion USD | 16.84% |
| 2020 FY | 30.41 Billion USD | 17.77% |
| 2020 Q2 | 6.71 Billion USD | 0.55% |
| 2020 Q1 | 6.67 Billion USD | -0.31% |
| 2019 FY | 25.82 Billion USD | 3.16% |
| 2019 Q1 | 6.13 Billion USD | -2.37% |
| 2019 Q2 | 6.43 Billion USD | 4.92% |
| 2019 Q3 | 6.55 Billion USD | 1.91% |
| 2019 Q4 | 6.69 Billion USD | 2.12% |
| 2018 Q1 | 6 Billion USD | 10.04% |
| 2018 FY | 25.03 Billion USD | 18.22% |
| 2018 Q4 | 6.28 Billion USD | -1.84% |
| 2018 Q3 | 6.4 Billion USD | 0.9% |
| 2018 Q2 | 6.34 Billion USD | 5.61% |
| 2017 Q1 | 4.92 Billion USD | -6.09% |
| 2017 FY | 21.17 Billion USD | 6.92% |
| 2017 Q4 | 5.45 Billion USD | 1.49% |
| 2017 Q2 | 5.41 Billion USD | 10.04% |
| 2017 Q3 | 5.37 Billion USD | -0.68% |
| 2016 Q3 | 4.92 Billion USD | -2.36% |
| 2016 Q4 | 5.24 Billion USD | 6.35% |
| 2016 FY | 19.8 Billion USD | 7.88% |
| 2016 Q1 | 4.58 Billion USD | -6.82% |
| 2016 Q2 | 5.04 Billion USD | 9.98% |
| 2015 Q3 | 4.77 Billion USD | 4.78% |
| 2015 FY | 18.35 Billion USD | 18.19% |
| 2015 Q4 | 4.92 Billion USD | 3.1% |
| 2015 Q2 | 4.55 Billion USD | 11.25% |
| 2015 Q1 | 4.09 Billion USD | -5.42% |
| 2014 Q2 | 3.81 Billion USD | 10.11% |
| 2014 Q1 | 3.46 Billion USD | -9.56% |
| 2014 FY | 15.53 Billion USD | 9.33% |
| 2014 Q4 | 4.33 Billion USD | 10.39% |
| 2014 Q3 | 3.92 Billion USD | 2.94% |
| 2013 Q4 | 3.82 Billion USD | 7.38% |
| 2013 Q3 | 3.56 Billion USD | -1.98% |
| 2013 Q2 | 3.63 Billion USD | 14.55% |
| 2013 Q1 | 3.17 Billion USD | -19.4% |
| 2013 FY | 14.2 Billion USD | 2.43% |
| 2012 Q1 | 3.01 Billion USD | -18.2% |
| 2012 FY | 13.87 Billion USD | 8.34% |
| 2012 Q2 | 3.42 Billion USD | 13.37% |
| 2012 Q3 | 3.49 Billion USD | 2.16% |
| 2012 Q4 | 3.94 Billion USD | 12.78% |
| 2011 Q1 | 2.68 Billion USD | 0.0% |
| 2011 Q3 | 3.26 Billion USD | 2.93% |
| 2011 Q4 | 3.68 Billion USD | 13.13% |
| 2011 Q2 | 3.16 Billion USD | 17.76% |
| 2011 FY | 12.8 Billion USD | 12.87% |
| 2010 FY | 11.34 Billion USD | 11.69% |
| 2009 FY | 10.15 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 34.31 Billion USD | -32.714% |
| Bristol-Myers Squibb Company Ce | 34.31 Billion USD | -32.714% |
| Johnson & Johnson | 58.6 Billion USD | 22.298% |
| Eli Lilly and Company | 27.04 Billion USD | -68.398% |
| Merck & Co., Inc. | 43.98 Billion USD | -3.521% |
| Novartis AG | 34.18 Billion USD | -33.199% |
| Organon & Co. | 3.74 Billion USD | -1114.995% |
| Pfizer Inc. | 28.8 Billion USD | -58.069% |